SLCO1A2 and prostate cancer: Elevated expression levels of OATP1B3 have been observed in prostate cancer, therefore, the current study employed four types of OATP inhibitor to test whether this subfamily of OATPs was involved in NIRF uptake in prostate cancer cells (6,21,22).